Role of novel biomarkers in diabetic cardiomyopathy
作者机构：Department of PathophysiologyUniversity of Split School of MedicineSplit 21000Croatia Department of EndocrinologyUniversity Hospital of SplitSplit 21000Croatia Emergency MedicineInstitute of Emergency Medicine of Split-Dalmatia CountySplit 21000Croatia
出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)
年 卷 期：2021年第12卷第6期
页 面：685-705页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Diabetic cardiomyopathy Heart failure Biomarkers Diabetes mellitus Cardiomyopathy
摘 要：Diabetic cardiomyopathy(DCM)is commonly defined as cardiomyopathy in patients with diabetes mellitus in the absence of coronary artery disease and *** DCM is now recognized as a cause of substantial morbidity and mortality among patients with diabetes mellitus and clinical diagnosis is still inappropriate,various expert groups struggled to identify a suitable biomarker that will help in the recognition and management of DCM,with little success so ***,we thought it important to address the role of biomarkers that have shown potential in either human or animal studies and which could eventually result in mitigating the poor outcomes of *** the array of biomarkers we thoroughly analyzed,long noncoding ribonucleic acids,soluble form of suppression of tumorigenicity 2 and galectin-3 seem to be most beneficial for DCM detection,as their plasma/serum levels accurately correlate with the early stages of *** combination of relatively inexpensive and accurate speckle tracking echocardiography with some of the highlighted biomarkers may be a promising screening method for newly diagnosed diabetes mellitus type 2 *** purpose of the screening test would be to direct affected patients to more specific confirmation *** perspective is in concordance with current guidelines that accentuate the importance of an interdisciplinary team-based approach.
维普期刊数据库